Optimal Antiplatelet Therapy in Patients After Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,703

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

April 30, 2030

Study Completion Date

November 30, 2030

Conditions
Chronic Coronary SyndromeStable Coronary Artery Disease CAD
Interventions
DRUG

High-Dose Aspirin 300 mg

High-dose Aspirin 300 mg once daily taken orally for three months

DRUG

DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg)

"Drug: Prasugrel 10 mg~Prasugrel 10 mg once daily taken orally for 3 months~Drug: Low-Dose Aspirin~75 mg once daily taken orally"

DRUG

Low-Dose Aspirin 75 mg

Low-Dose Aspirin 75 mg once daily taken orally

Trial Locations (18)

Unknown

University Clinical Hospital in Bialystok, Bialystok

Nicolaus Copernicus University Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz

Medical University of Gdansk, Gdansk

Regional Specialist Hospital in Grudziadz, Grudziądz

Upper-Silesian Heart Center, Katowice

John Paul II Hospital, Krakow

Medical University of Lodz, Lodz

"Zbigniew Religa Heart Center Medinet", Nowa Sól

Provincial Specialist Hospital in Olsztyn, Olsztyn

Institute of Medical Sciences in Opole, Opole

J. Struś Hospital, Poznan

Poznan University of Medical Sciences, Poznan

Pomeranian Medical University, Szczecin

Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw

Medicover Hospital, Warsaw

Wroclaw Medical University, Wroclaw

"Zbigniew Religa Heart Center Medinet", Wroclaw

Silesian Centre for Heart Diseases in Zabrze, Zabrze

Sponsors
All Listed Sponsors
collaborator

Medical Research Agency, Poland

OTHER_GOV

lead

Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.

OTHER

NCT07195149 - Optimal Antiplatelet Therapy in Patients After Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial) | Biotech Hunter | Biotech Hunter